Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,400
-1,200 (-8.22%)
Apr 30, 2026, 3:30 PM KST
Market Cap1.29T +160.9%
Revenue (ttm)3.52B -76.6%
Net Income-22.13B
EPS-0.21
Shares Out96.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,103,368
Average Volume2,046,897
Open14,280
Previous Close14,600
Day's Range13,370 - 14,440
52-Week Range4,325 - 21,500
Beta1.06
RSI45.68
Earnings DateMay 14, 2026

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2025, Hyundai Bioscience's revenue was 3.52 billion, a decrease of -76.63% compared to the previous year's 15.05 billion. Losses were -22.13 billion, 219.3% more than in 2024.

Financial Statements